Prot #D933SC00001: A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and Standard of Care Chemotherapy Ver

Project: Research project

StatusActive
Effective start/end date7/22/197/22/22

Funding

  • AstraZeneca Pharmaceuticals LP (Prot #D933SC00001)